tbuckley/cabot-search huggingface dataset:
Abstract 18322: No Short-term Mortality Benefit With Endovascular Therapy in Acute Ischemic Stroke: A Systematic Review and Meta-analysis
Authors: Sobia Khan, Hisham Salahuddin, Kent A Cabatingan, Faraz K Luni, Abdur R Khan, Mark A Buehler, Syed F Zaidi, Mouhammad A Jumaa, George V Moukarbel
Journal: Circulation (2015)

Background: The efficacy of endovascular treatment in improving functional outcome in acute ischemic stroke has been established. However, it is unclear if there is any beneficial effect on mortality in stroke patients undergoing prompt endovascular treatment. Methods: Ovid MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus were searched from inception through June 2015 for randomized controlled trials that compared endovascular treatment to the current standard of care in acute ischemic stroke. Studies were selected if they had short-term (90 day) mortality as a measured outcome. Mortality was pooled and odds ratio (OR) was calculated using the Mantel-Haenszel method using a fixed effect model. Results: There were 10 studies with 2835 participants in our analysis. There were 224/1513 (14.8%) deaths reported in the endovascular treatment arm and 214/1322 (16.2%) deaths in the current standard of care arm. There was no difference in 90 day mortality between endovascular treatment and current standard of care (OR 0.86, 95% CI= 0.70-1.06, p =0.51; I2 = 0%). The Figure shows forest plot comparing 90-day mortality in the endovascular treatment arm and the current standard of care arm in patients with acute ischemic stroke. There was visual estimation of publication bias which was not confirmed by trim and fill method. Conclusions: In this meta-analysis we did not find any short term mortality benefit with rapid endovascular treatment as compared to current standard of care. With the improvement demonstrated in functional outcomes, endovascular intervention represents a paradigm shift in stroke therapy. However, more studies are needed to look at both short and long-term survival and cost effectiveness of the modality.
PLoS Medicine Issue Image | Vol. 1(3) December 2004
Journal: PLoS Medicine (2004)

Several years ago my mother lost her battle with throat cancer. Shortly after, my brother was diagnosed with a fist-sized tumor in his brain; luckily he has been "cancer free" for many years now. After my brother's diagnosis, my mother-in-law was diagnosed with breast cancer, but she lost her battle with it. As one can imagine, situations such as these are extremely difficult to accept. We all have different ways of coping, and Cancer, as well as other images that I have produced, enabled me to overcome troubling experiences. The images I choose to tackle deal not only with the people in my life but also with the powerful experiences that we all face from time to time. Sometimes gifts come in unusual forms. The pain I have experienced has convinced me that life is simply too short to waste on anything other than that which is most important to me. I have quit my job in order to pursue a Masters of Fine Arts in painting at Arizona State University, and my beautiful wife and I are the proud parents of an equally beautiful 17-month-old daughter. Image Credit: Karl Gustav Kroeppler (kroeppler [at] cox.net)
Inspiratory Fall in Systolic Pressure in Normal and Asthmatic Subjects
Authors: Michael D. Goldman, Marc Mathieu, Jean Marc Montely, Rochelle Goldberg, June M. Fry, Jean Louis Bernard, Richard Sartene
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

We used a noninvasive monitor of arterial pressure to determine whether respiratory changes in arterial pressure were closely correlated with airflow obstruction in asthmatic patients during bronchial challenge with methacholine. To validate the noninvasive measurement of respiratory changes in arterial pressure, a preliminary study in 6 subjects with normal cardiovascular and respiratory systems was done during cardiac catheterization for suspected coronary artery disease. There were no significant differences between inspiratory falls in systolic pressure measured noninvasively and those measured from intraaortic pressure. In 11 otherwise healthy asthmatic patients we measured finger arterial pressure, end-expiratory lung volume (FRC), and forced expired volume (FEV1) during baseline and bronchial challenge in the supine posture. Finger arterial pressure was also measured in 11 normal control subjects seated and supine. Normal subjects had an inspiratory fall in systolic pressure (IFSP) of 3.2 mm Hg supine and 5.1 mm Hg seated (p < 0.01). Asthmatic patients when bronchodilated (seated FEV1 = 83 ± 7% of predicted) had an IFSP of 5.9 mm Hg supine (p < 0.01 compared with supine normal subjects). During bronchial challenge (average fall in FEV1 = 22%), IFSP increased to 16.1 mm Hg (p < 0.001 compared with baseline). In asthmatic subjects, there was a significant correlation between IFSP and FEV1 (mean r = −0.92 ± 0.05, p < 0.01), and the average change in IFSP/change in FEV1 was −0.38 mm Hg per percentage change in FEV1. During subsequent bronchodilation, IFSP decreased with a similar time course as relaxation of airway smooth muscle, assessed by the breath-to-breath fall in FRC. We conclude that measurement of IFSP from finger arterial pressure is a useful index of clinical state in asthmatic patients during moderate bronchoconstriction. The method is sensitive enough to detect differences between normal and bronchodilated asthmatic subjects and differences in normal subjects between upright and supine.
Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Authors: Tadeusz Robak, Andrzej Hellman, Janusz Kloczko, Javier Loscertales, Ewa Lech-Maranda, John M. Pagel, Anthony Mato, John C. Byrd, Farrukh T Awan, Holger Hebart, Jose A Garcia-Marco, Brian T. Hill, Michael Hallek, Scott Stromatt, Ulrich Jaeger
Journal: Blood (2013)
Narcotic Addiction: Where Will It End?
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RECTAL BINDER
Authors: A. J. Chisholm
Journal: JAMA (1922)

Having had difficulty in finding a suitable binder for use in cases following rectal operations, especially fistula, when the patient is required to wear a gauze pad for a few weeks, I designed the binder shown in the accompanying illustration, which, I believe, is superior to any so far used. The cost is nominal. The binder, which is adjustable, is supported by an arrangement of tapes fastened to a waistband. In detail, it is a cloth band (<i>a</i>) permanently fastened by one end, the back, to an elastic belt (<i>b</i>), which is provided with a buckle for "waist" adjustment. The other end of the cloth band is hemmed (<i>c</i>), so that this end of the band can slide on an elastic tape (<i>d</i>). The elastic tape is made in two parts having a buckle connection for adjustment, and its extreme ends slide on the elastic waistband (<i>b</i>). The plain end
A pilot feasibility study of gefitinib (ZD1839) and celecoxib in metastatic GI tumors
Authors: N. H. Yamaguchi, I. A. Mayer, A. Malzyner, C. J. C. Andrade, A. M. Murad, A. D. Giglio, H. Cardoso
Journal: Journal of Clinical Oncology (2004)

3086 Background: Gefitinib ('Iressa', ZD1839) is an EGFR-TKI (tyrosine kinase inhibitor) and celecoxib is a COX2 inhibitor with anti-inflammatory, anti-angiogenic, and anti-proliferative properties. In the early development of gefitinib, anecdotal responses were reported in GI tumors. Celecoxib (400 mg bid) has demonstrated activity in colorectal polyposis (Steinbach G, NEJM 2000). We hypothesized that the inhibition of both EGFR and COX2 are potential therapeutic targets in GI tumors. To date, the clinical use of this combination has not been reported in GI malignancies. Methods: A multicenter feasibility study of gefitinib 250 mg/day and celecoxib 400 mg bid was carried in patients with advanced GI malignancies. 16 men and 14 women with a median age of 58 years were recruited. All patients had more than one previous chemotherapeutic treatment. Primary tumors consisted of 25 colorectal, 3 pancreatic, 1 esophageal, and 1 gallbladder. All patients were enrolled in 2002 and 2003 and had signed an informed consent approved by the central IRB . All patients had available paraffin blocks for IH analysis on EGFR and COX2 expression. Results: By RECIST criteria, 3 patients (2 with colorectal cancer and 1 with pancreatic cancer) had confirmed stable disease and 27 patients had progressive disease. Adverse events (AEs) were generally mild and consisted mainly of acne, diarrhea, and nausea. No grade 3/4 AEs were reported. Dose reductions for celecoxib (to 200 mg bid) were reported for 5 patients due to gastrointestinal toxicity. Data on EGFR and COX2 expression in paraffin blocks will be presented at a future date. Conclusions: In chemotherapy refractory pretreated patients with advanced GI cancers, the combination of gefitinib and celecoxib is feasible and generally well tolerated. Further studies to identify a subgroup of patients that would benefit from this combination are warranted. 'Iressa' is a trademark of the AstraZeneca group of companies. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca
Orchid Food
Authors: Clayton J. Baker
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infant Mental Development Index: Hu et al. Respond
Authors: Howard Hu, Martha María Téllez-Rojo, Héctor Lamadrid-Figueroa, Adriana Mercado-García, Mauricio Hernández-Avila, David Bellinger, Donald Smith, Adrienne S. Ettinger, Joel Schwartz, Lourdes Schnaas
Journal: Environmental Health Perspectives (2007)
Human Immunodeficiency Virus Transmission in Household Settings—United States
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biliary Dyskinesia
Authors: W J Hogan, J E Geenen
Journal: Endoscopy (1988)

Delivery of bile into the duodenum involves a series of complex interrelationships between hepatic secretion of bile and pressure differentials generated within the gallbladder, cystic duct and sphincter of Oddi. Theoretically, functional disorders of bile flow may arise from a disturbance of any one of the above factors. A brief review of our present knowledge of the physiology of bile flow and the spectrum of functional biliary tract disorders will be outlined to help explain possible factors which may be involved in biliary tract dysmotility disturbances. The sphincter of Oddi (SO) mechanism is dedicated to maintaining a low pressure system within the hepatic ducts which allows hepatic secretion to proceed irrespective of bile flow rate. Partial obstruction at the SO segment can give rise to intermittent or persistent upper abdominal pain. We classify sphincter of Oddi (SO) motor dysfunction into two broad categories: 1. SO stenosis: defined as a structural narrowing of part or all of the SO segment, and 2) SO dyskinesia: defined as a primary disorder of SO tonic/phasic motor activity. We have attempted to deal with an overlap in etiology of SO motor dysfunction by developing patient group classifications. Biliary I-patients with biliary-type pain, abnormal liver function tests (SGOT; al PO4 greater than 2 x normal) documented on 2 or more occasions, delayed drainage of ERCP contrast greater than 45 min, and dilated CBD greater than 12 mm diameter; Biliary II-patients with biliary-type pain but only 1 or 2 of the above criteria; Biliary III-patients with only biliary-type pain and no other abnormalities. A few of these patients may have primary SO dyskinesia.
DILATATION OF STOMACH DUE TO COMPRESSION OF DUODENO-JEJUNAL JUNCTION BY MESENTERIC ARTERY, VEIN AND NERVE.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Meeting Spotlights Advances in Cancer Immunotherapy
Journal: JNCI Journal of the National Cancer Institute (1991)

Meeting Spotlights Advances in Cancer Immunotherapy Get access JNCI: Journal of the National Cancer Institute, Volume 83, Issue 24, 18 December 1991, Pages 1789–1790, https://doi.org/10.1093/jnci/83.24.1789 Published: 18 December 1991
Health system reform. Whither or whether?
Authors: P. J. Seward
Journal: JAMA (1995)

As early as 1990, the American Medical Association recognized the imperative for health system reform and advanced its own program called Health Access America.<sup>1</sup>Yet it was not until the campaign slogan of Harris Wofford and the promises of President Clinton that the great health system reform debate of the 1990s began. Many felt the need to extend insurance coverage, flatten the rise of health care expenditures, and to find new and innovative ways of providing cost-effective health care with an emphasis on preventive medicine. Public polls overwhelmingly indicate that the public believes the current system requires change, albeit without a clear indication of how. The medical profession as much as anyone sees the defects in the current system along with the intrusion of entrepreneurial giants and continues to declare the status quo unacceptable. Anticipation regarding possible reforms was high, activity frenetic, and expectations rampant, but the whole reform
Literature and Medicine
Authors: Larry R. Churchill
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction*1
Authors: M PRIETO
Journal: Hepatology (1995)

To determine whether the presence of hepatitis C virus (HCV) viremia correlates with the severity of liver disease in anti-HCV-positive apparently healthy blood donors, we studied 98 blood donors found positive for anti-HCV using enzyme-linked immunosorbent assay (ELISA). Each subject underwent a liver biopsy, a test for HCV RNA in the serum by polymerase chain reaction (PCR), and a panel of liver injury tests. As a result, 97% of the anti-HCV-positive blood donors had some type of histological abnormality: 22 (22%) had minimal changes, 1 (1%) had chronic lobular hepatitis, 40 (41%) had chronic persistent hepatitis (CPH), and 32 (33%) had chronic active hepatitis (CAH). Only 3 subjects had a normal liver histology. HCV RNA was detectable in the serum in 65% of the anti-HCV-positive donors. HCV RNA in serum was detectable in none of the donors with a normal liver histology, in 36% (confidence interval [ci], 17% to 59%) of those with minimal changes, in 70% (CI, 53% to 83%) of those with CPH, and in 87% (CI, 71% to 96%) of those with CAH (P = .00001). HCV RNA was detectable in 75% of the donors with elevated (> 45 U/L) alanine transaminase (ALT) values and in 59% of those with normal ALT levels (P = not significant). The incidence of chronic hepatitis was higher in HCV RNA-positive than in HCV RNA-negative donors (88% vs. 50%; P = .00005). By stepwise logistic regression, age older than 50 years (odds ratio = 17.5), an elevated ALT level (odds ratio = 74.4), and serum HCV RNA (odds ratio = 18.9) were independently associated with the presence of chronic hepatitis. In summary, in anti-HCV-positive blood donors the prevalence of HCV RNA in serum appears to correlate with the severity of liver injury and is greatest in CAH. The detection of serum HCV RNA in 36% of the donors with minimal changes on biopsy, all of them with normal ALT levels, suggests that a healthy HCV carrier state may exist.
A Method for In Vitro Culture of Rat Zymbal Gland: Use in Mechanistic Studies of Benzene Carcinogenesis in Combination with 32 P-Postlabeling
Authors: M. Vijayaraj Reddy, Gary R. Blackburn, Susan E. Irwin, Choudari Kommineni, Carl R. Mackerer, Myron A. Mehlman
Journal: Environmental Health Perspectives (1989)
MEXICO CITY
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Purified T Depleted Peripheral Blood and Bone Marrow Cd34 Transplantation from Haploidentical Mother to Child with Thalassemia.
Authors: Pietro Sodani, Buket Erer, Javid Gaziev, Paola Polchi, Andrea Roveda, Luca Spitaleri, Francesca Pagliai, Katia Paciaroni, Gaspare Adorno, Alessandro Lanti, Giancarlo Isacchi, Francesco Zinno, Guido Lucarelli
Journal: Blood (2006)
SURGICAL VERSUS MEDICAL TREATMENT IN DISEASE OF LEFT MAIN CORONARY ARTERY
Authors: WilliamC Taylor, StephenC Textor, IanM Graham, Noel Hickey, Risteárd Mulcahy, Leslie Daly, Albert Oberman, NicholasT Kouchoukos, RichardO Russell, JohnE Holt, MalcolmE Turner
Journal: The Lancet (1977)